Related Experiment Video

Updated: May 23, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with

Michel Dietz1, Peter Mohr, Bernd Kuhn

  • 1Discovery Technologies, F. Hoffmann-La Roche AG, Grenzacherstrasse 124, Basel 4070, Switzerland.

Chemmedchem
|April 11, 2012
PubMed

Insights

Aleglitazar, a dual PPARα/γ agonist, demonstrates high potency and balanced activation for treating type 2 diabetes and cardiovascular risk. Its efficacy is confirmed through cell-based assays and cofactor recruitment profiles.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Endocrinology

Background:

  • Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors regulating physiological processes.
  • PPARα and PPARγ agonism offers a therapeutic strategy for reducing cardiovascular risk factors.
  • Aleglitazar is an investigational dual PPARα/γ agonist for type 2 diabetes mellitus patients post-acute coronary event.

Purpose of the Study:

  • To evaluate the potency and efficacy of aleglitazar.
  • To compare aleglitazar head-to-head with other PPAR ligands (α, γ, and δ).
  • To analyze aleglitazar's cofactor recruitment profile and relate its activity to crystal structures.

Main Methods:

  • Cell-based assays with a 12-concentration dose-response analysis.
  • Evaluation of cofactor recruitment profiles.
  • Comparison with other PPAR ligands and consideration of X-ray crystal structures.

Main Results:

  • Aleglitazar exhibited high potency with EC50 values of 5 nM for PPARα and 9 nM for PPARγ.
  • Cofactor recruitment profiles confirmed aleglitazar as a potent and balanced activator of PPARα and γ.
  • Potency and efficacy were discussed in relation to other dual PPARα/γ agonists.

Conclusions:

  • Aleglitazar is a potent and balanced dual PPARα/γ agonist.
  • Its pharmacological profile supports its potential therapeutic application in managing type 2 diabetes and cardiovascular risk.
  • Further clinical development is warranted based on its demonstrated preclinical efficacy.

More Related Videos

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells07:22

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes: